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Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the
highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer 89Zr-
cetuximab and to assess tumour uptake.
Methods: Two dose schedules were used; two consecutive doses of 60 MBq 89Zr-cetuximab or a single
dose of 120 MBq, both preceded by 400 mg/m2 of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored
twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour
uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing
tumours.
Results: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with
administration of 89Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR) > 1
was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose sched-
ules. There was a trend for higher TBR at intervals > 5 days after injection.
Conclusions: Both presented 89Zr-cetuximab administration schedules are safe. The recommended dose
for future trials is 60 MBq, with a minimum time interval for scanning of 6 days.
 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 122 (2017) 267–273Monoclonal antibodies are increasingly used in anticancer
treatment to specifically target receptors at the surface of tumour
cells, either as a monotherapy or in combination with radiotherapy
or chemotherapy. Cetuximab is such a monoclonal antibody that
specifically blocks the epidermal growth factor receptor (EGFR)
which is over-expressed in many human malignancies [1,2]. EGFR
activation and overexpression appear to be important tumour cell
mechanisms in the development of resistance to radiation and
chemotherapy, resulting in decreased rates of local tumour control
and survival [3].
A randomized phase III trial in head and neck cancer showed
improved survival of adding cetuximab to radiotherapy [4]. In con-
trast, cetuximab combined with radiotherapy failed to show anybenefit over chemoradiotherapy [5], moreover, the addition of
cetuximab to chemoradiotherapy did not show benefit in head
and neck cancer [6] or non-small cell lung cancer [7,8]. Selection
of patients with the highest chance of benefit from cetuximab
treatment is of obvious relevance, also in view of its high costs.
The mechanisms underlying clinical response or resistance to
treatment against EGFR with cetuximab combined with radiother-
apy are, however, largely unknown [9,10].
Non-invasive visualization and quantification of tumour uptake
of cetuximab may contribute significantly to the selection of
patients and determination of the needed dosage [11]; several
methods using nuclear imaging have been proposed [12,13].
As the biologic half-life of cetuximab in blood is 65–95 h [14], a
radioactive tracer with a long half-life is needed to visualize its
uptake. Zirconium-89 (89Zr), with a half-life of approximately
78 h, is an example of such a positron emission tomography
(PET) tracer that can successfully be labelled to cetuximab and
has shown promising results in animal models [15–17]. In a
268 89Zr-cetuximab PET imaging in NSCLC and HNCpreclinical study, uptake of 89Zr-cetuximab was demonstrated only
in EGFR-positive tumours. However, it was shown that 89Zr-
cetuximab uptake did not correlate with EGFR expression levels,
implying that pharmacokinetic and -dynamic factors influence
the cetuximab accumulation in tumours [16].
Here, we report the results of a phase I study with primary aim
determining the safety of zirconium-89 labelled cetuximab, with
tumour 89Zr-cetuximab uptake as a secondary end point. Further-
more, we aimed to get an indication of the optimal radioactivity
dose and imaging time point to direct future phase II studies.Methods
Patient selection
Patients with a histologically confirmed solid cancer without
curative treatment options were eligible. Inclusion criteria were:
WHO performance status 0–2; adequate bone marrow, hepatic
and renal function; life expectancy > 3 months and written
informed consent. Patients with a recent (<3 months) myocardial
infarction, uncontrolled infectious disease, pregnancy, previous
administration of cetuximab or concurrent treatment with anti-
cancer agents or radiotherapy were excluded.Study design
A study design with two different dose schedules was used
(Fig. 1). In both steps, 89Zr-cetuximab was administered within
one hour after administration of the loading dose of unlabelled
cetuximab. Six patients were included, three in each dose schedule.
If in any patient grade 2 or higher toxicity was observed related to
89Zr-cetuximab administration, 3 extra patients would be included
in this dose step. When at maximum 1/6 patients experienced
grade 2 toxicity, the step was considered safe.
The study design anticipated the future aim, which is to deter-
mine the tumour uptake of 89Zr-cetuximab before and during ther-
apy. Therefore, in the first dose schedule (step 1), toxicity of two
consecutive low doses of 89Zr-cetuximab was investigated. A stan-
dard loading dose of 400 mg/m2 cetuximab, followed by 10 mg of
89Zr-cetuximab (60 MBq) was administered on day 0. A second
injection with a maintenance dose of 250 mg/m2 of cetuximab,*
Injecon Zr-cetuximab
400 mg/m2, 60 MBq
day 0 7
Step 1
day 0 7
Injecon Zr-cetuximab
400 mg/m2, 120 MBq
Step 2
* days of scanning in step 2 depend on imaging re
Fig. 1. Timeline of the study: 89Zr-cetuximab injection (grey arrows) and the acquiring of
after injection were optional and depended on the imaging results in step 1: If in step 1 tw
an additional scan on day 3 would be performed. If in step 1 two or more patients had a h
Patients included in step 3 were scanned at one time point only, based on the imagingfollowed by 10 mg of 89Zr-cetuximab (60 MBq) was administered
on day 14.
As a larger radioactivity dose of 89Zr-cetuximab is possibly
needed to obtain the best image quality, toxicity of a single larger
dose was investigated in a second dose schedule (step 2). A loading
dose of 400 mg/m2 of cetuximab was administered followed by
injection of 10 mg of cetuximab labelled with 120 MBq 89Zr.
During inclusion in step 2, a study amendment was written
based on the first results of the image analysis. It was decided that
if the secondary endpoint (assessment of tumour 89Zr-cetuximab
uptake) could not be satisfactorily assessed based on the first 6
patients, a third step would be added in which 3 patients were
included with an EGFR overexpressing tumour based on recent
immunohistochemistry. For these patients, the administration
schedule was the same as in step 2.
The study protocol was approved by the medical ethical com-
mittee and the radiation safety committee. The study is listed in
clinicaltrials.gov number NCT00691548.EGFR expression and mutation status
In all patients, biopsies of the primary tumour were taken
before the start of treatment. For patients included in step 3, a
recent biopsy of the primary tumour or from a metastatic lesion
had to be available, without any antitumour treatment between
the biopsy and inclusion. After inclusion, EGFR expression and
mutation status (exons 18–21) as well as KRAS mutation (codons
12 and 13) were assessed on these biopsies [18]. EGFR expression
was analysed with the EGFR pharmDx qualitative immunohisto-
chemical kit system (Novocastra and Dako, Denmark). To quantify
EGFR expression, both EGFR membrane staining intensity and the
percentage of EGFR expressing cells were taken into account. EGFR
membrane staining intensity was expressed as a score between 0
(none) and 3+(strong). The percentage of cells staining at different
intensities was assessed visually. Subsequently, EGFR immunohis-
tochemistry (IHC) scores were defined on a scale of 0–300 using a
formula combining percentage of staining cells and staining inten-
sity [19]. Tumours were divided in showing low and high EGFR-
expression on basis of a score <200 and P200, a threshold based
on the results of the FLEX study [20,21].28
Injecon Zr-cetuximab
250 mg/m2, 60 MBq
14 21
14 21 28
sults in step 1
89Zr-cetuximab PET/CT scans (black arrows). In step 2, PET-CT scans on days 3 and 7
o or more patients had a higher tumour to blood ratio (TBR) on day 4 than on day 5,
igher TBR on day 6 than on day 5, an additional scan on day 7 would be performed.
results of steps 1 and 2.
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Toxicity was assessed during treatment and twice weekly
thereafter until 14 days after the last injection, according to the
CTCAE 3.0 scoring system. At baseline and on days 7 and 14 after
injection, blood testing was performed for haematology, kidney
and liver function.
The most common side effect of cetuximab administration that
was anticipated for was skin toxicity (acneform rash) [22]. As skin
toxicity is a known side effect of unlabelled cetuximab administra-
tion and this trial aimed to investigate the safety of labelled cetux-
imab, skin toxicity was not regarded as a dose limiting side effect.Li
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Synthesis of 89Zr-cetuximab
89Zr was produced by a (p,n) reaction on natural 89Y as
described by Verel et al. [23]. Subsequently, labelling of 89Zr to
the mAb cetuximab was performed as previously reported [24].r-
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ofPET-CT imaging
PET-CT imaging was performed at days 4, 5 and 6 after injection
in dose step 1. Imaging intervals in step 2 were adapted based on
the TBRs at subsequent days in step 1. Patients included in step 3
were scanned at one time point only, based on the imaging results
of steps 1 and 2. Furthermore, an optional 18F-fluorodeoxyglucose
(FDG-)PET scan was performed within the study period, at least
24 h before or 12 days after 89Zr-cetuximab administration (P4
times the half-life of cetuximab). In the first patient that under-
went an FDG-PET scan after the 89Zr-cetuximab administration,
an extra PET-CT scan was performed at day 12, preceding
FDG-injection, to assess remaining activity associated with the
89Zr -cetuximab administration.Ta
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t.Image analysis
Tumour sites and normal tissues were manually delineated on
one of the 89Zr-cetuximab PET-CT scans (day 6 or 7) by the same
observer (JvL). For one patient, delineations were performed on
the FDG-PET-CT scan. Tumour sites were delineated based on the
CT using FDG-PET information when available. To quantify uptake
in muscle and liver, a transversal CT slice of the subscapular muscle
and the liver was delineated. The resulting regions of interest were
subsequently projected onto the other 89Zr-cetuximab-PET-CT
scans and FDG-PET scan through co-registration of the correspond-
ing CT images using rigid registration.
The mean, maximum and peak standardized uptake value
(SUVmean, SUVmax and SUVpeak, respectively) were determined
using in-house developed dedicated software. The tumour SUVpeak
was defined by calculating the mean SUV in a sphere with a diam-
eter of 1.2 cm within the tumour region with the highest activity.
Tumour to background ratio (TBR) was calculated by dividing
tumour SUVpeak by SUVmean in the aortic arch.
For patients in whom an additional 18F-FDG-PET scan was per-
formed, the 18FDG and 89Zr-cetuximab uptake was visually
compared.
Results
Patient characteristics are shown in Supplementary Table 1,
tumour characteristics in Table 1. Nine patients, with a median
age of 62 years (range: 53–75), were included. The third patient
was excluded from the study before injection of 89Zr-labelled
cetuximab, because of malignant hypertension during
administration of the unlabelled cetuximab. The blood pressure
normalized within two hours of observation without further
Fig. 2. 89Zr-cetuximab PET maximum intensity projections of all patients. The GTV of the primary tumour is overlaid in blue. The notes underneath the images indicate in
which dose step the patients were included, how many days post injection the displayed images were acquired and the dose of 89Zr-cetuximab (2  60 MBq or 1  120 MBq)
administered. The scans with the highest TBR in the primary tumour were selected. For dose step 1, the images after the first injection were analysed.
270 89Zr-cetuximab PET imaging in NSCLC and HNCconsequences. Therefore an extra patient (patient 4) was included
in dose step 1. Only 2 patients were included in step 3 of the study.
Given the slow accrual, and since this step was not necessary to
reach the primary endpoint, it was decided to close this step
prematurely.
From the 9 patients included, 6 had non-small cell lung cancer
(NSCLC) and 3 had head and neck cancer (HNC). All patients had
previously undergone anti-cancer therapy. In one patient, EGFR
expression and mutation and KRAS mutation status of the primary
tumour could not be assessed due to insufficient quantity of histo-
logical material. In the other patients, 6 of the 7 primary tumours
showed high EGFR expression, while none showed a mutation of
the EGFR gene. An example of IHC staining in a biopsy with high
EGFR expression is shown in Supplementary Fig. 1 (Patient 6). In
the only patient with low EGFR expression, the primary tumour
showed a mutation in the KRAS gene. One of the two patients
included in step 3 showed high EGFR expression on a recent
tumour biopsy. The recent specimen of the second patient con-
tained insufficient material to allow a reliable EGFR analysis.
Each patient received 89Zr-cetuximab administration as
planned. Patients included in steps 1 and 2 underwent the
89Zr-PET-CT scans at 3 consecutive days, except for patient 6
who could not undergo the first scan due to pain. Patient 4,
included in step 1, was scanned at day 5–7 instead of day 4–6
because of logistical reasons. In two patients (patient 2 and 4)enrolled in the first dose step, the series of PET-CT scans after the
second injection could not be performed due to pain and dyspnoea.
Patients included in step 3 were scanned at day 6 after injection.
Four patients underwent an FDG-PET scan within the study period,
at an interval of 12 or 13 days after the injection of 89Zr-cetuximab.
An overview of the toxicity per patient is presented in Supple-
mentary Table 2. No toxicity other than skin rash was observed
in any of the patients. Of the eight patients that received the full
cetuximab administration, three experienced grade 1, and 4 expe-
rienced grade 2 acne form rash. No changes were observed for
haematological, kidney and liver function compared to baseline.
89Zr-cetuximab-PET images of all patients are shown in Fig. 2
(coronal) and Fig. 3 (transversal). Tumour and normal tissue
uptake values of 89Zr-cetuximab are shown in Table 1. All but
one patient had a peak TBR > 1 at any of the imaging time points.
For each patient, the 89Zr-cetuximab image with the highest TBR
was selected for further analyses. For patient in dose step 1, only
the scans after the first 89Zr-cetuximab injection were analysed
since for two of the three patients PET/CT could not be acquired
in the second week. The average peak TBR was 2.39 (range
0.96–4.56). The average tumour SUVmax and SUVmean were 6.02
(range: 1.62–7.84) and 1.99 (range 0.79–3.15), respectively. The
average SUVmax and SUVmean for the liver were 9.71 (range:
6.98–18.42) and 7.48 (range 5.26–12.47). For muscle, the average
SUVmax and SUVmean were 1.79 (range: 0.97–3.41) and 0.44 (range
89Zr-cetuximab FDG
p5
p6
p7
p1
0 7 0 11
Fig. 4. Correlation between 89Zr-cetuximab and 18FDG uptake for the four patients
receiving both scans. PET uptake is shown in SUV. The primary tumour is delineated
in blue. The 89Zr-cetuximab scans with the highest TBR in the primary tumour were
selected.
p1 p2
p4 p5
p6 p7
p8 p9
0 7
Fig. 3. 89Zr-cetuximab PET-CT images at tumour level showing uptake in SUV. The
primary tumour is delineated in blue. The scans with the highest TBR in the primary
tumour were selected.
J. van Loon et al. / Radiotherapy and Oncology 122 (2017) 267–273 2710.21–0.75). Both SUVmax and SUVmean of the tumour were signifi-
cantly higher than the muscle SUVmax and mean.
The 18FDG-PET and 89Zr-cetuximab uptake of the four patients
who had an FDG-PET-CT scan is shown in Fig. 4. Visual comparison
showed a remarkable mismatch between FDG and 89Zr-cetuximab
uptake in one patient (patient 1, Fig. 4A).
No direct relationship was observed between the EGFR IHC
score and TBR.
For the patients in dose step 1, the average peak TBR at days 4, 5
and 6 after the first injection was 1.33 (range: 1.23–1.43), 2.06
(range: 1.67–2.65) and 3.12 (range: 1.68–4.56), respectively
(Fig. 5). As the highest TBR was found at day 6 after injection, imag-
ing in dose step 2 was performed at days 5, 6 and 7. For patients in
dose step 2, the average peak TBR at days 5, 6 and 7 after injection
was 1.65 (range: 0.94–2.37), 1.64 (range: 0.96–2.71) and 1.96
(range: 0.94–3.20) (Fig. 5). The peak TBR of patients included in
step 3 was 1.35 and 1.46 (day 6). At the regular imaging time
points, the highest peak TBR was seen in patient 4 (4.56), at day
6 after injection. In patient 1, an extra PET-CT scan was performed
at day 12 after injection. The TBR at this time point was higher than
the maximum TBR for this patient at the regular imaging time
points (2.78 and 1.68, respectively).Discussion
The current phase I trial is the first study in HNC and NSCLC
evaluating the safety of 89Zr-cetuximab. It is a first step towardsa new patient selection method for cetuximab treatment or the
addition of cetuximab to radiotherapy. 89Zr-cetuximab has until
now only been evaluated in human patients with colorectal cancer
[25]. In this study, no additional toxicity was associated with
89Zr-cetuximab administration. Acne form eruption 6 grade 2
was observed in 88% of patients, a rate comparable to that found
with therapeutic administration of cetuximab [4,22,26]. One
patient developed malignant hypertension during the administra-
tion of unlabelled cetuximab. Although rare, this side-effect has
been described previously [27].Tumour uptake of 89Zr-cetuximab
It should be emphasized that no definitive conclusions can be
drawn given the small amount of patients as well as the hetero-
geneity in tumour type and previous anticancer treatment. All
but one patient that completed the study protocol showed a peak
TBR > 1. Visually, however, the 89Zr-cetuximab images showed a
rather patchy distribution, without an evident specific uptake of
89Zr-cetuximab within the tumour. Visually comparing the
89Zr-cetuximab images of NSCLC and HNC patients, more dis-
cernible tumour uptake appeared to be present in at least one of
the HNC patients (Fig. 3G).
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Fig. 5. 89Zr-cetuximab tumour to blood ratios at different time points after injection of the tracer. The patients displayed with a black line were included in dose step 1; the
patients with a grey line in dose step 2; the patients with a single black marker in dose step 3.
272 89Zr-cetuximab PET imaging in NSCLC and HNCNo direct relationship was observed between EGFR IHC score
and TBR, similar to the findings in our preclinical study [16]. There
are several considerations that argue a direct relationship between
EGFR expression at a biopsy specimen and response to cetuximab
treatment. Firstly as expression of EGFR can be induced by radia-
tion and chemotherapy, it is possible that an initially EGFR nega-
tive tumour may become positive early during therapy, thereby
still benefiting from cetuximab treatment [28,29]. Secondly, EGFR
expressing tumours will not respond to cetuximab when cetux-
imab does not reach therapeutic concentrations in the tumour
because of e.g. interstitial pressure and vascular perfusion changes
[30].Recommended 89Zr-cetuximab dose and time interval for scanning
A large divergence was observed in the time curves of the TBR.
Hence, no optimal imaging time point can be derived from these
data. However, we advise a time delay of at least 6 days after injec-
tion, as 5 of the 6 patients that were scanned at days 5 and 6
showed a higher TBR at day 6. This is in line with a study in col-
orectal cancer that also found an optimal scanning time point
6 days post injection [25]. In the only patient that was scanned
after a substantially longer time interval (12 days after administra-
tion), the highest TBR was found at this time point. This late rise in
TBR suggests that a later imaging time point might result in more
optimal tumour visualization. Due to decay, however, accurate
quantification at such late time intervals may be biased by
increased noise levels.
Although no definitive conclusions can be drawn regarding the
dosage of labelled cetuximab in view of the different tumour char-
acteristics in the two dose schedules, the current results do not
indicate that a higher dose would result in more optimal TBRs.
Therefore, taking into account the ALARA (as low as reasonably
achievable) principle, a dose of 60 MBq of 89Zr-cetuximab is rec-
ommended for future study.Recommendations for further study
There are some other factors of which the influence on tumour
visualization should be assessed in future studies. First, the loading
dose administered in this study (400 mg/m2), which is the stan-
dard therapeutic regimen, might be suboptimal to enable adequatetumour visualization. A loading dose of cetuximab is required as
cetuximab first binds irreversibly to EGFR expressing liver cells,
and tumour cells are only targeted after the liver has been satu-
rated. This rationale is supported by animal studies as well as by
the positive relation between skin toxicity and tumour response
to cetuximab, implying that skin saturation only occurs after the
liver has been saturated [31,32]. The liver SUVmax and SUVmean in
the current trial were rather high, implying that EGF receptors of
the liver were still not saturated by the loading dose.
Based on the promising clinical results of adding cetuximab to
radiotherapy in head and neck cancer [4], and the imaging data
from the current study suggesting specific 89Zr-cetuximab uptake
in at least one of the HNC patients, a clinical trial was started in this
patient group (e.g. in the ARTFORCE head and neck trial, clinicaltri-
als.gov: NCT01504815 [33]). Unfortunately, due to slow accrual,
complexity of 89Zr-cetuximab imaging for both patients and radio-
therapy departments, and discontinuation of the funding of cetux-
imab, the study was amended and 89Zr-cetuximab imaging and
cetuximab treatment were discontinued.
In conclusion, the administration of 89Zr-cetuximab to image
in vivo cetuximab uptake is safe and not associated with any addi-
tional toxicity compared to unlabelled cetuximab. The recom-
mended time interval between cetuximab administration and
scanning is at least 6 days. The recommended 89Zr-cetuximab dose
is 60 MBq. Further research is needed to explore the optimal load-
ing dose of non-labelled cetuximab and the relationship with EGFR
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